DOCSLIB.ORG

Information for the User Bupivacaine Hydrochloride 1Mg/Ml and Fentanyl

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Information for the User Bupivacaine Hydrochloride 1Mg/Ml and Fentanyl Package leaflet: Information for the user Bupivacaine Hydrochloride 1mg/ml and Fentanyl Citrate 2 micrograms/ml Solution for infusion Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml Solution for infusion Bupivacaine Hydrochloride/Fentanyl Citrate Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or nurse. • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4. The name of your medicine is Bupivacaine Hydrochloride 1mg/ml and Fentanyl Citrate 2 micrograms/ml Solution for infusion and Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml Solution for infusion. It will be referred to as Bupivacaine and Fentanyl infusion for ease hereafter. What is in this leaflet 1. What Bupivacaine and Fentanyl infusion is and what it is used for 2. What you need to know before you are given Bupivacaine and Fentanyl infusion 3. How Bupivacaine and Fentanyl infusion will be given to you 4. Possible side effects 5. How to store Bupivacaine and Fentanyl infusion 6. Contents of the pack and other information This medicine contains fentanyl which is an opioid, which can cause addiction. You can get withdrawal symptoms if you stop taking it suddenly. 1. WHAT BUPIVACAINE AND FENTANYL INFUSION IS AND WHAT IT IS USED FOR This medicine is a mixture of two active ingredients: Bupivacaine, which is a local anaesthetic, a medicine used to numb areas of your body in order to relieve pain and Fentanyl (as citrate), which is used to treat pain. This medicine has been prescribed for you for the treatment of pain during labour and after operations. It contains the fentanyl which belongs to a class of medicines called opioids, which are ‘pain relievers’. This medicine has been provided to you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely. It will be given to you in hospital under the supervision of an anaesthetist, in an epidural (injection into the lower back). 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN BUPIVACAINE AND FENTANYL INFUSION You should not be given Bupivacaine and Fentanyl infusion by an epidural • if you are allergic to bupivacaine, fentanyl or any of the other ingredients of this medicine (listed in section 6) • if you have been given a type of local anaesthesia known as a Biers block • if you have been given a type of local anaesthesia that numbs the cervix during childbirth • if you are suffering from inflammation or skin infection at the site of the proposed injection • if you have problems with blood clotting or you are taking medicines to stop your blood clotting • if you have a heart problem known as complete heart block • if you are currently having difficulty breathing or you suffer from asthma • if you have suffered a head injury or are suffering from a disease that affects the brain or the nerves in your spine such as meningitis, poliomyelitis, brain or spinal tumours, developmental spinal problems such as spina bifida, tuberculosis of the spine, blood vessel malformations or bleeding in the brain • if you are suffering from shock caused by a lack of blood or problems with your blood circulation (symptoms of this include feeling weak, cold or pale skin, breathing quickly and anxiety) • if you are currently taking drugs used to treat depression known as monoamine oxidase inhibitors (MAOIs) or have taken them in the last 2 weeks • if you have consumed excessive amounts of alcohol • if you are suffering from a blood disorder known as pernicious anaemia. Warnings and precautions Talk to your doctor or nurse before you are given Bupivacaine and Fentanyl infusion if you have: • a disorder that causes fits such as epilepsy • any heart problems including, low or high blood pressure, fast or slow heartbeats • liver or kidney problems • problems with your adrenal glands • problems with your thyroid • prostate enlargement in men • disease of the nervous system, such as Myasthenia gravis (a disorder with weak muscles) • breathing problems • you are taking any medicine from the group of medicines known as benzodiazepines. Taking these medicines with Bupivacaine and Fentanyl infusion may result in sedation, difficulties in breathing (respiratory depression), coma and may be fatal. Even if benzodiazepines are prescribed, your doctor may need to change the dose, the duration of treatment or monitor you regularly. Talk to your prescriber before taking this medicine if you: • are or have ever been addicted to opioids, alcohol, prescription medicines, or illegal drugs. • have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating, when you have stopped taking alcohol or drugs. • feel you need to take more of Bupivacaine and Fentanyl infusion to get the same level of pain relief, this may mean you are becoming tolerant to the effects of this medicine or are becoming addicted to it. Speak to your prescriber who will discuss your treatment and may change your dose or switch you to an alternative pain reliever. Taking this medicine regularly, particularly for a long time, can lead to addiction. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely. Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your prescriber about your treatment. Addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your prescriber will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid, may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. Special care will be taken when this medicine is being given to the elderly and ill. If any of the above apply to you, please consult your doctor. Other medicines and Bupivacaine and Fentanyl infusion Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines, including those obtained without prescription. You must not be given Bupivacaine and Fentanyl infusion if you are taking: • drugs used to treat severe depression, such as phenelzine or moclobemide or if you have stopped taking them within the last 2 weeks. These drugs are known as Monoamine Oxidase Inhibitors (MAOIs) • medicines used to stop your blood clotting (anticoagulants). Tell your doctor if you are taking any of the following medicines that may interact with Bupivacaine and Fentanyl infusion: • medicines used to treat irregular heartbeats such as amiodarone • medicines that depress the nervous system such as sleeping pills or those that may cause drowsiness or are used to help you to relax (anxiolytics) such as barbiturates • medicines used to treat mental disorders (antipsychotics) such as chlorpromazine and droperidol • medicines used to treat high blood pressure such as propranolol • general anaesthetics such as propofol and nitrous oxide • strong painkillers such as morphine and codeine • cimetidine which is used to treat stomach ulcers • the antiviral drug ritonavir • concomitant use of Bupivacaine and Fentanyl infusion and sedative medicines such as benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. However, if your doctor does prescribe Bupivacaine and Fentanyl infusion together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking and follow your doctor’s dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms. If you have any doubts about whether this medicine should be given to you, consult your doctor, nurse or pharmacist. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before being given this medicine. Pregnancy Do not take Bupivacaine and Fentanyl infusion if you are pregnant or think you might be pregnant unless you have discussed this with your prescriber and the benefits of treatment are considered to outweigh the potential harm to the baby. If you use Bupivacaine and Fentanyl infusion during pregnancy, your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated. Breastfeeding Do not take Bupivacaine and Fentanyl infusion while you are breastfeeding as fentanyl passes into breast milk and will affect your baby. Driving and using machines Bupivacaine and Fentanyl infusion may affect your ability to drive or operate machinery. If you are discharged from hospital soon after receiving this medicine and plan to resume these activities, ask your doctor when it will be safe to do so.
Load more

Recommended publications
  • Bupivacaine Injection Bp
    PRODUCT MONOGRAPH INCLUDING CONSUMER INFORMATION BUPIVACAINE INJECTION BP Bupivacaine hydrochloride 0.25% (2.5 mg/mL) and 0.5% (5 mg/mL) Local Anaesthetic SteriMax Inc. Date of Preparation: 2770 Portland Dr. July 10, 2015 Oakville, ON, L6H 6R4 Submission Control No: 180156 Bupivacaine Injection Page 1 of 28 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................................... 3 INDICATIONS AND CLINICAL USE ......................................................................................... 3 CONTRAINDICATIONS .............................................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................................. 4 ADVERSE REACTIONS ............................................................................................................... 9 DRUG INTERACTIONS ............................................................................................................. 10 DOSAGE AND ADMINISTRATION ......................................................................................... 13 OVERDOSAGE ........................................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY ....................................................................... 18 STORAGE
    [Show full text]
  • Bupivacaine Hcl Rx Only 0.5% with Epinephrine 1:200,000 (As Bitartrate) (Bupivacaine Hydrochloride and Epinephrine Injection, USP)
    Bupivacaine HCl Rx only 0.5% with epinephrine 1:200,000 (as bitartrate) (bupivacaine hydrochloride and epinephrine injection, USP) THIS SOLUTION IS INTENDED FOR DENTAL USE. DESCRIPTION Bupivacaine hydrochloride is (±) -1-Butyl-2´,6´-pipecoloxylidide monohydrochloride, monohydrate, a white crystalline powder that is freely soluble in 95 percent ethanol, soluble in water, and slightly soluble in chloroform or acetone. It has the following structural formula: Epinephrine is (-)-3,4-Dihydroxy-α-[(methylamino)methyl] benzyl alcohol. It has the following structural formula: BUPIVACAINE HCl is available in a sterile isotonic solution with epinephrine (as bitartrate) 1:200,000. Solutions of BUPIVACAINE HCl containing epinephrine may not be autoclaved. BUPIVACAINE HCl is related chemically and pharmacologically to the aminoacyl local anesthetics. It is a homologue of mepivacaine and is chemically related to lidocaine. All three of these anesthetics contain an amide linkage between the aromatic nucleus and the amino or piperidine group. They differ in this respect from the procaine-type local anesthetics, which have an ester linkage. CLINICAL PHARMACOLOGY BUPIVACAINE HCl stabilizes the neuronal membrane and prevents the initiation and transmission of nerve impulses, thereby effecting local anesthesia. The onset of action following dental injections is usually 2 to 10 minutes and anesthesia may last two or three times longer than lidocaine and mepivacaine for dental use, in many patients up to 7 hours. The duration of anesthetic effect is prolonged by the addition of epinephrine 1:200,000. It has also been noted that there is a period of analgesia that persists after the return of sensation, during which time the need for strong analgesic is reduced.
    [Show full text]
  • Local Anesthetics
    Local Anesthetics Introduction and History Cocaine is a naturally occurring compound indigenous to the Andes Mountains, West Indies, and Java. It was the first anesthetic to be discovered and is the only naturally occurring local anesthetic; all others are synthetically derived. Cocaine was introduced into Europe in the 1800s following its isolation from coca beans. Sigmund Freud, the noted Austrian psychoanalyst, used cocaine on his patients and became addicted through self-experimentation. In the latter half of the 1800s, interest in the drug became widespread, and many of cocaine's pharmacologic actions and adverse effects were elucidated during this time. In the 1880s, Koller introduced cocaine to the field of ophthalmology, and Hall introduced it to dentistry Overwiev Local anesthetics (LAs) are drugs that block the sensation of pain in the region where they are administered. LAs act by reversibly blocking the sodium channels of nerve fibers, thereby inhibiting the conduction of nerve impulses. Nerve fibers which carry pain sensation have the smallest diameter and are the first to be blocked by LAs. Loss of motor function and sensation of touch and pressure follow, depending on the duration of action and dose of the LA used. LAs can be infiltrated into skin/subcutaneous tissues to achieve local anesthesia or into the epidural/subarachnoid space to achieve regional anesthesia (e.g., spinal anesthesia, epidural anesthesia, etc.). Some LAs (lidocaine, prilocaine, tetracaine) are effective on topical application and are used before minor invasive procedures (venipuncture, bladder catheterization, endoscopy/laryngoscopy). LAs are divided into two groups based on their chemical structure. The amide group (lidocaine, prilocaine, mepivacaine, etc.) is safer and, hence, more commonly used in clinical practice.
    [Show full text]
  • Local Anesthetics – Substances with Multiple Application in Medicine
    ISSN 2411-958X (Print) European Journal of January-April 2016 ISSN 2411-4138 (Online) Interdisciplinary Studies Volume 2, Issue 1 Local Anesthetics – Substances with Multiple Application in Medicine Rodica SÎRBU Ovidius University of Constanta, Faculty of Pharmacy, Campus Corp B, University Alley No. 1, Constanta, Romania Emin CADAR UMF Carol Davila Bucharest, Faculty of Pharmacy, Str. Traian Vuia No. 6, Sector 2, Bucharest, Romania Cezar Laurențiu TOMESCU Ovidius University of Constanta, Faculty of Medicine, Campus Corp B, University Alley No. 1, Constanta, Romania Cristina-Luiza ERIMIA Corresponding author, [email protected] Ovidius University of Constanta, Faculty of Pharmacy, Campus Corp B, University Alley No. 1, Constanta, Romania Stelian PARIS Ovidius University of Constanta, Faculty of Pharmacy, Campus Corp B, University Alley No. 1, Constanta, Romania Aneta TOMESCU Ovidius University of Constanta, Faculty of Medicine, Campus Corp B, University Alley No. 1, Constanta, Romania Abstract Local anesthetics are substances which, by local action groups on the runners, cause loss of reversible a painful sensation, delimited corresponding to the application. They allow small surgery, short in duration and the endoscopic maneuvers. May be useful in soothe teething pain of short duration and in the locking of the nervous disorders in medical care. Local anesthesia is a process useful for the carrying out of surgery and of endoscopic maneuvers, to soothe teething pain in certain conditions, for depriving the temporary structures peripheral nervous control. Reversible locking of the transmission nociceptive, the set of the vegetative and with a local anesthetic at the level of the innervations peripheral nerve, roots and runners, a trunk nervous, around the components of a ganglion or coolant is cefalorahidian practice anesthesia loco-regional.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • World Health Organization Model List of Essential Medicines, 21St List, 2019
    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]
  • A Brief History Behind the Most Used Local Anesthetics
    Tetrahedron xxx (xxxx) xxx Contents lists available at ScienceDirect Tetrahedron journal homepage: www.elsevier.com/locate/tet Tetrahedron report XXX A brief history behind the most used local anesthetics * Marco M. Bezerra, Raquel A.C. Leao,~ Leandro S.M. Miranda, Rodrigo O.M.A. de Souza Biocatalysis and Organic Synthesis Group, Chemistry Institute, Federal University of Rio de Janeiro, 21941-909, Brazil article info abstract Article history: The chemistry behind the discovery of local anesthetics is a beautiful way of understanding the devel- Received 13 April 2020 opment and improvement of medicinal/organic chemistry protocols towards the synthesis of biologically Received in revised form active molecules. Here in we present a brief history based on the chemistry development of the most 16 September 2020 used local anesthetics trying to draw a line between the first achievements obtained by the use of Accepted 18 September 2020 cocaine until the synthesis of the mepivacaine analogs nowadays. Available online xxx © 2020 Elsevier Ltd. All rights reserved. Keywords: Anesthetics Medicinal chemistry Organic synthesis Mepivacaíne Contents 1. Introduction . ............................. 00 1.1. Pain and anesthesia . ............................................... 00 1.2. Ancient techniques to achieve anesthesia . ............................... 00 1.3. The objective of this work . .......................................... 00 2. Cocaine .............................................................................................. ............................
    [Show full text]
  • SABER®-Bupivacaine
    SABER®-Bupivacaine Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee 16 January 2020 1 SABER-Bupivacaine SPONSOR PRESENTATION 2 Sponsor presentation Speaker Topic Tong J. Gan, MD, MHS, FRCA, MBA Clinical context Professor and Chairman, Dept. of Anesthesiology Stony Brook School of Medicine Neil Verity, PhD Introduction to clinical program Executive Director, Pharmacology DURECT Corporation Project leader and principal scientist Jon Meisner, MD Efficacy and safety Sr. Medical Director, Medical Affairs DURECT Corporation Asok Doraiswamy, MD, FACS General surgeon’s perspective Methodist Hospital of Southern California Huntington Memorial Hospital Harold Minkowitz, MD Anesthesiologist’s perspective Memorial Hermann Katy Hospital Memorial Hermann Memorial City Medical Center 3 Reserve speakers Speaker Title/Affiliation James M. Anderson, MD, PhD Professor of Pathology Case Western Reserve University Nathaniel Katz, MD, MS Adjunct Assistant Professor of Anesthesia, Tufts University School of Medicine Chief Science Officer, WCG-Analgesic Solutions Lynne Steinbach, MD Emeritus Professor of Radiology on Full Recall Department of Radiology and Biomedical Imaging University of California San Francisco Julie Thacker MD, FACS, FASCRS Associate Professor with Tenure Department of Surgery Duke University School of Medicine Linval DePass, PhD, DABT, Principal Scientist and Executive Director, ATS Fellow Nonclinical Safety, DURECT Corporation David J. Ellis, MD, PhD Vice President, Clinical Development DURECT Corporation William
    [Show full text]
  • Package Leaflet: Information for the Patient Bupivacaine Hydrochloride 0.25% W/V Solution for Injection and Bupivacaine Hydrochloride 0.5% W/V Solution for Injection
    Package leaflet: Information for the patient Bupivacaine Hydrochloride 0.25% w/v Solution for Injection and Bupivacaine Hydrochloride 0.5% w/v Solution for Injection READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If you get any side effects, talk to your doctor, or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. The name of your medicine is Bupivacaine Hydrochloride 0.25% w/v Solution for Injection, Bupivacaine Hydrochloride 0.5% w/v Solution for Injection. It will be referred to as Bupivacaine Hydrochloride Injection for ease hereafter. In this leaflet: 1. What Bupivacaine Hydrochloride Injection is and what it is used for 2. What you need to know before you are given Bupivacaine Hydrochloride Injection 3. How to take Bupivacaine Hydrochloride Injection 4. Possible side effects 5. How to store Bupivacaine Hydrochloride Injection 6. Contents of the pack and other information 1. WHAT BUPIVACAINE HYDROCHLORIDE INJECTION IS AND WHAT IT IS USED FOR Bupivacaine belongs to a group of medicines called amidetype anaesthetics. Bupivacaine Hydrochloride injection is used to numb (anaesthetise) parts of the body. It is used to stop pain happening or to provide pain relief. It can be used to: · Numb parts of the body during surgery in adults and children above 12 years · Relieve pain in adults, infants and children above 1 year of age.
    [Show full text]
  • Interventions for Relieving Pain Associated with Panretinal
    Eye (2006) 20, 712–719 & 2006 Nature Publishing Group All rights reserved 0950-222X/06 $30.00 www.nature.com/eye 1 2 1 1 CLINICAL STUDY Interventions W-C Wu , K-H Hsu , T-L Chen , Y-S Hwang , K-K Lin1, L-M Li1, C-P Shih2 and C-C Lai1 for relieving pain associated with panretinal photocoagulation: a prospective randomized trial Abstract mefenamic acid, and acetaminophen (either alone or in combination with each other) are Purpose To evaluate the efficacy of pain relief not effective in preventing PRP treatment- by oral diazepam, acetaminophen, mefenamic associated pain. Intramuscular injection of 1Department of acid, intramuscular ketorolac tromethamine, ketorolac tromethamine is also not effective in Ophthalmology, Chang and peribulbar anaesthesia in panretinal reducing PRP-associated pain. Gung Memorial Hospital, photocoagulation (PRP). Eye (2006) 20, 712–719. doi:10.1038/sj.eye.6701989; Taoyuan, Taiwan Methods A total of 220 patients with published online 8 July 2005 proliferative diabetic retinopathy requiring 2The Department of Business Administration, PRP treatment were enrolled in this study. Keywords: peribulbar anesthesia; pain; Chang Gung University, Before laser treatment, the patients were panretinal photocoagulation Taoyuan, Taiwan allocated randomly to one of eight groups: group 1: diazepam (n ¼ 22), group 2: Introduction Correspondence: C-C Lai, acetaminophen (n ¼ 21), group 3: mefenamic Department of acid (n ¼ 21), group 4: diazepam and Panretinal photocoagulation (PRP) is an Ophthalmology, Chang Gung Memorial Hospital, acetaminophen (n ¼ 22), group 5: diazepam effective treatment in reducing severe visual 5 Fu-Hsin St, Kwei-Shan, and mefenamic acid (n ¼ 22), group 6: loss in patients with proliferative diabetic 333, Taoyuan, peribulbar anaesthesia with lidocaine (n ¼ 23), retinopathy (PDR).
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Inhibitory Effects of Lappaconitine on the Neuronal Isoforms of Voltage-Gated Sodium Channels
    www.nature.com/aps ARTICLE Inhibitory effects of lappaconitine on the neuronal isoforms of voltage-gated sodium channels Yan-fen Li1,2, Yue-ming Zheng2,3, Yong Yu4, Yong Gan2,3 and Zhao-bing Gao2,3 Lappaconitine (LA) has been widely used for postoperative and cancer pain control. LA exhibits excellent analgesic activity with a longer effective time than common local anesthetics such as tetracaine and bupivacaine. However, the mechanisms underlying the featured analgesic activity of LA remain largely unknown. Here, we report that LA is an inhibitor of voltage-gated sodium channel 1.7 (Nav1.7) stably expressed in human embryonic kidney (HEK293) cells. LA inhibited Nav1.7 in a voltage-dependent manner with an IC50 value (with 95% confidence limits) of 27.67 (15.68–39.66) µmol/L when the cell was clamped at −70 mV. In comparison with the quick and reversible inhibition of Nav1.7 by tetracaine and bupivacaine, the inhibitory effect of LA was rather slow and irreversible. It took more than 10 min to achieve steady-state inhibition when LA (300 µmol/L) was administered. Unlike tetracaine and bupivacaine, LA affected neither the voltage-dependent activation nor the inactivation of the channels. Five residues in domain III and domain IV have been reported to be critical for the effects of the two local anesthetics on Nav channels. But our mutant study revealed that only two residues (F1737, N1742) located in domain IV were necessary for the inhibitory activity of LA. The slow onset, irreversibility, and lack of influence on channel activation and inactivation accompanied with the different molecular determinants suggest that LA may inhibit Nav1.7 channels in a manner different from local anesthetics.
    [Show full text]